Cocrystal Pharma Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

COCP$1.03-6.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Nine months ended September 30,
2024 · 2023
Operating activities:
Net loss	$(14,238)		$(13,520)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	98		149
Right of use assets	247		163
Stock-based compensation	558		643
Operating lease liabilities	(142)		(172)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,281		401
Tax credit receivable	238		166
Accounts payable and accrued expenses	(1,367)		830
Net cash used in operating activities	(13,325)		(11,340)
Investing activities:
Purchases of property and equipment	(8)		(59)
Net cash used in investing activities	(8)		(59)
Financing activities:
Payments on finance lease liabilities	-		(7)
Proceeds from sale of common stock to related entities, net of transaction costs	-		4,000
Net cash provided by financing activities	-		3,993
Net decrease in cash and restricted cash	(13,333)		(7,406)
Cash and restricted cash at beginning of period	26,428		37,219
Cash and restricted cash at end of period	$13,095		$29,813
Supplemental disclosure:
Non-cash investing and financing activities
Initial recognition of right-of-use assets and lease liabilities	$163	$	-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.